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External beam radiotherapyIntroduction: There is evidence to support use of external beam radiotherapy (EBRT) in combination with
both low dose rate brachytherapy (LDR–EBRT) and high dose rate brachytherapy (HDR–EBRT) to treat
intermediate and high risk prostate cancer.
Methods: Men with intermediate and high risk prostate cancer treated using LDR–EBRT (treated between
1996 and 2007) and HDR–EBRT (treated between 2007 and 2012) were identified from an institutional
database. Multivariable analysis was performed to evaluate the relationship between patient, disease
and treatment factors with biochemical progression free survival (bPFS).
Results: 116 men were treated with LDR-EBRT and 171 were treated with HDR–EBRT. At 5 years, bPFS
was estimated to be 90.5% for the LDR–EBRT cohort and 77.6% for the HDR–EBRT cohort. On multivariable
analysis, patients treated with HDR–EBRT were more than twice as likely to experience biochemical pro-
gression compared with LDR–EBRT (HR 2.33, 95% CI 1.12–4.07). Patients with Gleason 8 disease were
more than five times more likely to experience biochemical progression compared with Gleason 6 disease
(HR 5.47, 95% CI 1.26–23.64). Cumulative incidence of grade 3 genitourinary and gastrointestinal tox-
icities for the LDR–EBRT and HDR–EBRT cohorts were 8% versus 4% and 5% versus 1% respectively,
although these differences did not reach statistical significance.
Conclusion: LDR–EBRT may provide more effective PSA control at 5 years compared with HDR–EBRT.
Direct comparison of these treatments through randomised trials are recommended to investigate this
hypothesis further.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Dose escalation has been shown to result in improved biochem-
ical progression free survival (bPFS) in localised prostate cancer(PCa) [1]. Doses of up to approximately 80 Gy can be delivered
using external beam radiotherapy (EBRT) [2]. However, with
brachytherapy (BT), steep dose gradients mean it is possible to
deliver greater dose escalation, while meeting dose constraints of
adjacent organs at risk (OAR), than would be possible with external
beam radiotherapy (EBRT) [3]. BT can also be combined with EBRT
to achieve even greater dose escalation [4,5].
Several studies, including randomised controlled trials (RCT), of
patients with intermediate and high risk localised PCa have
reported improved bPFS for both high dose rate BT (HDR) in
combination with EBRT (HDR–EBRT) and low dose rate permanent
seed BT (LDR) in combination with EBRT (LDR–EBRT) when com-
pared to EBRT alone [6–17]. However, there is a lack of randomised
evidence directly comparing LDR–EBRT with HDR–EBRT.
2 F. Slevin et al. / Clinical and Translational Radiation Oncology 20 (2020) 1–8Variable toxicity rates have been reported for HDR–EBRT and
LDR–EBRT [3,8,9,12,17–19]. In a RCT comparing HDR–EBRT with
EBRT alone, the reported incidence of grade 3 genitourinary
(GU) and gastrointestinal (GI) toxicities at 5 years were 26% and
7% respectively [8]. In comparison, 5 year cumulative grade 3
GU and GI toxicities of 18.4% and 8.1% were reported in the
ASCENDE-RT study of LDR–EBRT versus dose escalated external
beam radiotherapy (DE-EBRT) [20].
Advantages of HDR over LDR may include greater consistency of
dose distribution for target volume coverage and normal tissue
sparing, absence of seed migration and potentially lower costs
[2]. If, as has been estimated, PCa has a low alpha/beta ratio, and
therefore potentially greater susceptibility to large doses per frac-
tion, it has been suggested that there could also be radiobiological
advantages in favour of HDR [2,21].
Patients have been treated at our centre using both LDR–EBRT
and HDR–EBRT, thereby presenting an opportunity to compare
outcomes for these two treatments.2. Materials and methods
2.1. Patient population
Between 1996 and 2012, 347 men consecutively treated for
intermediate and high risk PCa using a combination of EBRT and
BT boost at a single cancer centre were retrospectively identified
from an institutional database. Patients were classified using the
NCCN criteria. Intermediate risk disease was defined as the pres-
ence of one or more of the following factors: T2b disease, prostate
specific antigen (PSA) >10 ng/ml or Gleason score 7 (ISUP Grade 2
or 3). High risk disease was defined as the presence of one or more
of the following factors: T2c disease, PSA >20 ng/ml or Gleason
score 8 (ISUP Grade 4 or 5). Clinical staging used the AJCC TNM
7 system. Bone scintigraphic studies were performed for patients
with high risk disease to exclude skeletal metastatic disease.
Cross-sectional pelvic imaging was undertaken using MRI. 60
patients without record of a post implant PSA (because they were
referred from other oncology centres) were excluded from the
analysis in this study (48 treated with HDR–EBRT and 12 treated
with LDR–EBRT), leaving 287 patients eligible for inclusion.2.2. Treatment
2.2.1. LDR boost
Between 1996 and 2007, LDR–EBRT was used to treat patients
with intermediate and high risk PCa. We previously described
our LDR technique and long term outcomes following LDR
monotherapy for localised PCa [22,23]. The aim was to achieve a
minimum peripheral dose of 110 Gy (prescribed as per TG43
guidelines) to the prostate capsule with a 3 mm isometric margin
(except posteriorly where no margin was applied). Initially, a two
step planning technique using the Seattle method was used with
prostate volume estimated by transrectal ultrasound (TRUS). From
2000, most patients were treated using a single step technique.
TRUS based pre-planning objectives during this period included
the prostate volume covered by 100% of the prescription dose
(Vp100) of greater than 99% and a dose to 90% of the prostate
(D90) of approximately 140 Gy. The D90 planned was expected
to be higher than achieved. The mean central dose had an objective
of less than 150% and a constraint for the rectal mucosal volume
which received 100% (Vr100) of the prescription dose to be less
than 1 cc. Urethra was not contoured as a separate structure. Post
implant dosimetry was not mandatory during the time period cov-
ered by this study.2.2.2. HDR boost
Between 2007 and 2012, HDR–EBRT was used to treat patients
with intermediate and high risk PCa. HDR boost was performed
under real time TRUS guidance. 14–20 needles were inserted into
the prostate via a perineal template. Once the needles were posi-
tioned, the prostate and any seminal vesicle (SV) involvement were
contoured and a 3 mm margin (isotropic apart from posteriorly)
was added to generate the planning target volume (PTV). OAR (ure-
thra and outer rectal wall) were outlined on ultrasound. Oncentra
Prostate treatment planning software (Elekta AB, Stockholm, Swe-
den) was used to prospectively plan treatment delivery to provide
an optimal dose distribution to target volume while minimising
dose to OARs. Between 2007 and 2010, a dose fractionation of
17 Gy in 2 fractions delivered 1 week apart was used. From 2010,
a single 15 Gy fraction was used. The use of a PTV in the treatment
planning process was introduced for the single fraction regime,
prior to this plans for the two fraction regime were optimised to
the GTV only.
TRUS based planning objectives included the prostate plus any
seminal vesicle involvement covered by the prescription dose
(V100) of greater than 95% for both fractionation regimes. The
PTV objective, VPTV100 greater than 90%, was introduced for the
single fraction regime. Dose to 10% of the urethra (Durethra10%)
was to be less than 10.25 Gy per fraction for the two fraction
cohort and 17.5 Gy for the single fraction cohort. The rectum dose
constraint is D2cc (minimum dose to the most irradiated 2 cc) less
than 78.8% of the prescription dose.
2.2.3. EBRt
LDR boost was combined with 45 Gy in 20 fractions of EBRT to
the prostate and SV delivered using 3D CRT. HDR boost delivered as
17 Gy in 2 fractions was combined with 35.75 Gy in 13 fractions of
EBRT to the prostate and SV. HDR boost of 15 Gy in 1 fraction was
combined with 37.5 Gy in 15 fractions of EBRT. Delivery of EBRT
commenced 2–3 weeks after the BT boost. Volumetric modulated
arc therapy (VMAT) was introduced from 2011.
2.2.4. Androgen deprivation therapy (ADT)
The majority of the patients received ADT, either by 3 monthly
LHRH agonist subcutaneous injection (Prostap 11.25 mg or Zoladex
10.8 mg) or bicalutamide 150 mg once daily tablet. Duration of
ADT varied between 6 and 36 months based on PCa risk stratifica-
tion. Where it was administered, ADT was commenced as neoadju-
vant therapy 3 months prior to the BT implant and the remaining
course was given as adjuvant therapy.
2.2.5. Follow up
As per our departmental protocol, patients were followed up
using PSA at 6 monthly intervals for the first 3 years post treatment
and annually thereafter. Biochemical relapse was defined by a PSA
of plus 2 ng/ml above the nadir value post treatment.
2.3. Study endpoints
The primary endpoint of this study is to compare bPFS in the
LDR–EBRT and HDR–EBRT groups. The secondary endpoint is to
report the cumulative incidence of grade 3 or greater crude GU
and GI toxicities.
2.4. Statistical analysis
Statistical analysis was performed using IBM SPSS version 21
(IBM, USA). Baseline patient and treatment characteristics for the
LDR–EBRT and HDR–EBRT groups were compared using a
chi-squared independence test for categorical variables and a two
sample t-test for continuous variables. Duration of follow up was
Table 1
Comparison of baseline patient, disease and treatment characteristics between LDR–
EBRT and HDR–EBRT groups.
LDR–EBRT
n = 128
HDR–EBRT
n = 219
p value
Evaluable patients 116 171
Missing data 12 (9.5%) 48 (22%)
Median follow up
(range)
74.1 months (1.0–
187)
57.0 months (1.8–
116)
Median age (range) 63 years (36–75) 65 years (49–76) 0.02
Median PSA value
(range)
10.7 ng/ml (1.6–
59)
10 ng/ml (1.4–
131)
Not
significant
Gleason score (ISUP Grade)
F. Slevin et al. / Clinical and Translational Radiation Oncology 20 (2020) 1–8 3calculated from the time of the BT procedure. Actuarial bPFS sur-
vival curves were generated using the Kaplan-Meier method. Cox
proportional hazards regression model was used for univariable
(UVA) and multivariable analysis (MVA) to assess factors associ-
ated with biochemical relapse free survival. The following vari-
ables were analysed by UVA: age, PSA, T stage, Gleason score,
NCCN risk group, duration of ADT and treatment group. Variables
with p value <0.2 on UVA were included in the MVA. Univariable
logistic regression analysis was performed to investigate factors
asociated with PSA control at 4 years. A p value of <0.05 was taken
to indicate a statistically significant difference between factors in
the LDR–EBRT and HDR–EBRT groups.6 (1) 17 (15%) 20 (12%)
7 (2 or 3) 76 (65%) 121 (71%) Not
significant
8–10 (4 or 5) 21 (18%) 29 (17%)
Unknown 2 (2%) 1 (<1%)
T stage
T1c-T2c 50 (43%) 69 (40%)
T3a-T3b 56 (48%) 97 (57%) Not
significant
Unknown 10 (9%) 5 (3%)
NCCN risk group
Low 2 (2%) 2 (1%)
Intermediate 28 (24%) 68 (40%)
High 80 (69%) 94 (55%) 0.02
Unknown 6 (5%) 7 (4%)
Hormone duration
12 months 74 (64%) 126 (74%)
>12 months 7 (6%) 27 (16%) 0.06
Unknown 35 (30%) 18 (10%)
Fig. 1. A Kaplan-Meier plot showing proportions of patients treated with LDR–EBRT
(blue curve) and HDR–EBRT (green curve) remaining free of biochemical progres-
sion. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)3. Results
3.1. Comparison of baseline characteristics
116 and 171 patients were evaluable in the LDR–EBRT and
HDR–EBRT groups respectively. A comparison of baseline patient,
disease and treatment characteristics between the LDR–EBRT and
HDR–EBRT groups is shown in Table 1. The median duration of fol-
low up for the LDR–EBRT and HDR–EBRT groups was 74.1 months
and 57 months respectively. There were no statistically significant
differences between the two groups in terms of PSA, Gleason score,
T stage and duration of ADT administration. Patients treated with
LDR–EBRT were slightly younger at baseline (median age: 63 years
versus 65 years, p = 0.02). The LDR–EBRT group contained a greater
proportion of patients with high risk PCa (69% (LDR–EBRT) versus
55% (HDR–EBRT, p = 0.02), while more patients in the HDR–EBRT
group had intermediate risk disease (40% (HDR–EBRT) versus 24%
(LDR–EBRT), p = 0.02).
3.2. HDR dosimetry
For HDR boost using 17 Gy in 2 fractions (utilised 2007–2010),
median prostate D90 per fraction was 9.46 Gy (range 8.92–
10.4 Gy) and median prostate V100 was 98.5% (range 93.5–
100%). For HDR boost using 15 Gy in 1 fraction (utilised 2010–
2012), median prostate D90 was 17.2 Gy (range 16.1–17.9 Gy)
and median prostate V100 was 99.6% (range 94.7–100%).
3.3. Biochemical progression free survival
Fig. 1 illustrates bPFS for LDR–EBRT and HDR–EBRT patients. At
3 and 5 years, bPFS was 94.1% and 90.5% for LDR–EBRT and 93.7%
and 77.6% for HDR–EBRT respectively. There was a statistically sig-
nificant difference in bPFS at 5 years in favour of LDR–EBRT com-
pared with HDR–EBRT (p = 0.01). Table 2 summarise the results
of UVA and MVA. Gleason score of 8 (ISUP Grade group 4 and
5) and treatment with HDR–EBRT both predicted for biochemical
relapse on MVA. The HDR–EBRT group were more than twice as
likely to experience biochemical progression compared with the
LDR–EBRT group (HR 2.33, 95% CI 1.12–4.07) and patients with
Gleason score 8 (ISUP Grade group 4 and 5) disease were more
than five times more likely to progress compared with those with
Gleason score 6 (ISUP Grade group 1) (HR 5.47, 95% CI 1.26–23.64).
3.4. PSA metrics
The median PSA in unrelapsed patients at the time of last follow
up was 0.11 ng/ml (range 0.01–1.97) in the LDR–EBRT group com-
pared with 0.26 ng/ml (0.07–1.6) in HDR–EBRT group. 82 of 116
(70.7%) and 97 of 171 (56.7%) patients in LDR–EBRT and HDR–EBRT
groups were followed up for a minimum of 4 years respectively. Of
these, 52 and 15 patients in the LDR–EBRT and HDR–EBRT groupshad a PSA <0.1 at time of last follow up respectively. On logistic
regression analysis, this difference was statistically significant
(OR 0.25, 95% CI 0.13–0.45, p = <0.001). Age, baseline PSA, Gleason
Fig. 3. Graph showing cumulative incidence of grade 3 gastrointestinal toxicity
for patients treated using LDR–EBRT (blue curve) and HDR–EBRT (green curve),
p = 0.13. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Fig. 2. Graph showing cumulative incidence of grade 3 genitourinary toxicity for
patients treated using LDR–EBRT (blue curve) and HDR–EBRT (green curve),
p = 0.17. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Table 2
Univariable and multivariable analyses for biochemical progression free survival.
Variable analysed by UVA p value Hazard ratio (95% CI) Variable analysed by MVA p value Hazard ratio (95% CI)
Age 0.44 0.99 (0.95–1.02) Gleason (ISUP) score
7 vs 6 (2 or 3 vs 1)
8 vs 6 (4 or 5 vs 1)
0.21
0.02
2.48 (0.58–10.46)
5.47 (1.26–23.64)
PSA 0.029 1.01 (1–1.03) Treatment group
HDR–EBRT vs LDR–EBRT
0.01 2.33 (1.22–4.42)
Gleason (ISUP)
7 vs 6 (2 or 3 vs 1) 0.31 1.84 (0.56–5.98)
8 vs 6 (4 or 5 vs 1) 0.04 3.7 (1.09–12.56)
T stage
T1/2 vs T3 0.50 1.2 (0.7–2.06)
NCCN risk group
Intermediate vs low 0.95 0.94 (0.12–7.13)
High vs low 0.83 1.24 (0.17–9.03)
Treatment group
HDR–EBRT vs LDR–EBRT 0.004 2.3 (1.31–4.09)
Duration of ADT
>12 months vs <12 months 0.01 2.3 (1.2–4.43)
4 F. Slevin et al. / Clinical and Translational Radiation Oncology 20 (2020) 1–8score, T stage, risk group and use of androgen deprivation were all
non-significant.
3.5. Toxicity
The 5 year cumulative incidence of grade 3 or above GU toxicity
was 8% and 4% in the LDR–EBRT and HDR–EBRT groups respec-
tively, although this difference was not statistically significant
(p = 0.17). The 5 year cumulative incidence of grade 3 or above GI
toxicity was 5% and 1% for the LDR–EBRT and HDR–EBRT groups
respectively. Again, this difference was not statistically significant
(p = 0.13). Figs. 2 and 3 illustrate cumulative incidence curves for
grade 3 or above GU and GI toxicities respectively.
4. Discussion
This retrospective study compared long term bPFS and late GU
and GI toxicity outcomes for men with intermediate and high risk
PCa treated with LDR–EBRT or HDR–EBRT treated in a single cen-
tre. At 5 years, bPFS was 90.5% for the LDR–EBRT group versus77.6% for the HDR–EBRT group. On MVA, HDR–EBRT was associ-
ated with a greater than doubling of the risk of biochemical failure
compared to LDR–EBRT. Patients with Gleason score 8 (ISUP
Grade group 4 or 5) were associated with a greater than five times
increased risk of failure. Although cumulative GU and GI grade 3 or
above toxicities were greater in the LDR–EBRT group, this differ-
ence was not statistically significant.
Both LDR–EBRT and HDR–EBRT are recommended as treat-
ments for men with intermediate and high risk PCa by American
Society of Clinical Oncology (ASCO), American Brachytherapy Soci-
ety, National Institute for Health and Care Excellence (NICE) and
European Association of Urology [24–28]. No RCTs directly com-
paring LDR–EBRT with HDR–EBRT have been reported, although
one is currently in progress (ClinicalTrials.gov Identifier
NCT03426748). However, there are studies demonstrating benefits
for combination LDR and HDR with EBRT compared with EBRT
alone including DE-EBRT. A recent analysis of over 120,000
patients from the National Cancer Database concluded that overall
survival was similar between patients treated with LDR–EBRT and
HDR–EBRT [29].
Table 3
Comparison of the results of our study with selected previously published studies of LDR–EBRT and HDR–EBRT.
Author Year Type of study Treatment Number of
patients
NCCN risk
category
Numbers
receiving
whole pelvis
RT
Biochemical PFS Late GU toxicity Late GI toxicity
Slevin,
Rodda
et al.
2019 Retrospective
cohort
LDR–EBRT versus HDR–
EBRT
LDR–EBRT:
116
HDR–EBRT:
171
LDR–EBRT:
Low 2 (2%)
Intermediate (Int.)
28 (24%)
High 80 (69%)
Unknown 6 (5%)
HDR–EBRT:
Low 2 (1%)
Int. 68 (40%)
High 94 (55%)
Unknown 7 (4%)
None LDR–EBRT: 90.5% at
5 years
HDR–EBRT: 77.6% at
5 years
LDR–EBRT: Cumulative grade 3 8%
at 5 years
HDR–EBRT: Cumulative grade 3 4%
at 5 years
LDR–EBRT: Cumulative grade
3 5% at 5 years
HDR–EBRT: Cumulative grade
3 1% at 5 years
Morris et al.
[12]
2017 RCT LDR–EBRT versus DE-
EBRT
LDR–EBRT:
198
DE-EBRT: 200
LDR–EBRT:
Int. 59 (29.8%)
High 139 (70.2%)
DE-EBRT:
Int. 63 (31.5%)
High 137 (68.5%)
All patients LDR–EBRT: 89% at
5 years, 83% at 9 years
DE-EBRT: 84% at 5 years,
62% at 9 years
LDR–EBRT: Cumulative grade 3
18.4% at 5 years
DE-EBRT: Cumulative grade 3 5.2%
at 5 years
LDR–EBRT: Cumulative grade
3 8.1% at 5 years
DE-EBRT: Cumulative grade 3
3.2% at 5 years
Lawton
et al. [9]
2012 Phase II trial LDR–EBRT 138 Int. 138 (100%) None 82% at 8 years Estimates of grade 3 15% at 8 years Estimates of grade 3 15% at
8 years
Shilkrut
et al. [15]
2013 Retrospective
cohort
LDR–EBRT versus DE-
EBRT
LDR–EBRT:
448
DE-EBRT: 510
LDR–EBRT:
High 448 (100%)
DE-EBRT:
High 510 (100%)
All patients LDR–EBRT:
89% at 5 years, 87% at
8 years
DE-EBRT:
73% at 5 years, 60% at
8 years
Toxicity data not presented Toxicity data not presented
Abughrahib
et al. [18]
2017 Retrospective
cohort
LDR–EBRT versus EBRT LDRT-EBRT:
191
EBRT: 388
LDR–EBRT:
Int. 191 (100%)
EBRT:
Int. 388 (100%)
None LDR–EBRT:
94.1% at 5 years, 91.7% at
10 years
EBRT: 89.2% at 5 years,
75.4% at 10 years
LDR–EBRT: Cumulative incidence of
grade 3 3.6% at 6 years, 7.5% at
10 years
EBRT: Cumulative incidence of
grade 3 1.4% at 6 years, 1.4% at
10 years
LDR–EBRT: Cumulative
incidence of grade 2 31.2% at
6 years, 35.5% at 10 years
EBRT: Cumulative incidence of
grade 2 33.1% at 6 years,
33.1% at 10 years
Hoskin et al.
[8]
2012 RCT HDR–EBRT versus EBRT HDR–EBRT:
110
EBRT: 106
HDR–EBRT:
Low 2 (2%)
Int. 48 (44%)
High 60 (54%)
EBRT:
Low 7 (7%)
Int. 43 (40%)
High 56 (53%)
None HDR–EBRT: 75% at
5 years, 46% at 10 years
EBRT: 61% at 5 years, 39%
at 10 years
HDR–EBRT: Incidence of grade 3
26% at 5 years, 31% at 7 years
EBRT: Incidence of grade 3 26% at
5 years, 30% at 7 years
HDR–EBRT: Incidence of
grade 3 7% at 5 years, 7% at
7 years
EBRT: Incidence of grade 3 6%
at 5 years, 6% at 7 years
Helou et al.
[7]
2015 Sequential
phase II
studies
Single 15 Gy versus two
10 Gy fraction boosts
HDR–EBRT
Single fraction
boost HDR–
EBRT: 123
Two fraction
boost HDR–
EBRT: 60
Single fraction
boost HDR–EBRT:
Int. 123 (100%)
Two fraction boost
HDR–EBRT:
Int. 60 (100%)
None Single fraction boost
HDR–EBRT: 97.4% at
5 years, 89.1% at 7 years
Two fraction boost HDR–
EBRT: 92.7% at 5 years,
92.7% at 7 years
Toxicity data for single 15 Gy arm
presented by Shahid et al. [3]
Toxicity data for single 15 Gy
arm presented by Shahid et al.
[3]
(continued on next page)
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studies, making direct comparison of our study with published
data difficult. Several studies included treated patients with whole
pelvis radiotherapy, unlike our study. In addition, there are often
differences in the baseline characteristics between studies, such
as the proportions of patients with intermediate and high risk dis-
ease. Nevertheless, our outcomes for the LDR–EBRT and HDR–EBRT
groups are not dissimilar to previously published studies. A com-
parison is shown in Table 3. The ASCENDE-RT study of LDR–EBRT
compared with DE-EBRT reported 5 year bPFS of 89% for patients
treated with LDR–EBRT [12]. A phase II study by Lawton et al.
reported 8 year bPFS of 82% and in retrospective cohorts 5 year
bPFS ranged from 89% to 94.1% at 5 years [9,15,18]. The RCT of
HDR–EBRT by Hoskin et al. reported 5 year bPFS of 75% [8]. At
5 years, Helou et al. reported bPFS was 97.4% and 92.7% in sequen-
tial phase II studies of a single 15 Gy HDR boost and two 10 Gy
fraction boosts respectively [7]. Retrospective series reported bPFS
at 5 years ranging from 82.5% to 97.7% [6,17,19]. It should be noted
that those studies with bPFS at 5 years for HDR–EBRT in excess of
90% had more patients with intermediate risk disease and fewer
with high risk disease [6,7,19].
Nadir PSA is an important predictor of longterm bPFS in men
treated with prostate BT and a lower PSA nadir is associated with
a better outcome [30]. Radiobiological models suggested that
LDR and HDR should provide similar tumour control, with a poten-
tial advantage for the high dose per fraction used with HDR if PCa
does indeed have a low alpha/beta ratio [2,21,31]. However, 44.8%
of patients treated with LDR–EBRT in our study achieved an abla-
tive PSA <0.1 compared with 8.7% treated with HDR–EBRT, despite
having a greater proportion of patients with high risk disease. It
has been shown that increasing biological effective dose (BED) is
associated with improved disease control. However, a different
BED equation is used for LDR calculations and there are difficulties
in comparing BEDs between LDR and other treatments [32,33]. The
dose rate and fractionation and intrinsic radiobiological properties
of LDR differ significantly to HDR [34]. Given the differences in
nadir PSA we have observed, it is possible that the improved out-
comes demonstrated in our study for patients treated with LDR–
EBRT are related to radiobiological advantages compared with
HDR–EBRT.
There are limitations to comparing our toxicity data with pub-
lished studies because of its retrospective nature and differences
in scoring systems, methods and timings of analyses, frequency
of follow up and dose fractionation schedules of LDR–EBRT and
HDR–HDR–EBRT [8]. We have also only reported grade 3 toxici-
ties and have not collected patient reported outcomes, which more
accurately measure adverse events [35]. A comparison of our
results with previously published studies is shown in Table 3.
Our study found lower cumulative 5 year grade 3 GU and GI tox-
icities for LDR–EBRT than in the ASCENDE-RT trial and the study by
Lawton et al. [9,20]. Cumulative grade 3 events were 18.4% and
8.1% for GU and GI toxicities at 5 years in the ASCENDE-RT study
and 15% at 8 years in the Lawton et al. study compared with 8%
and 5% respectively in our study. The differences observed com-
pared to our study may be because of stricter patient follow up
protocols used within these trials and the use of whole pelvis treat-
ments in the ASCENDE-RT study. In addition, the ASCENDE-RT
study used a BT boost of 115 Gy compared with 110 Gy in our
cohort [12]. Our study had low rates of significant late toxicity in
the HDR–EBRT group that compare favourably with published
studies. We found cumulative grade 3 GU and GI toxicities of
4% and 1% respectively. Hoskin et al. reported grade 3 GU and
GI toxicity rates at 5 years of 26% and 7% respectively [8]. Shahid
et al. reported incidence of grade 3 GU and GI toxicities of 4%
and 0% respectively in a phase II study of HDR–EBRT [3].
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patients eligible for analysis with both biochemical control and
toxicity endpoints reported. Limitations of this study that could
have influenced the differences in outcomes include its non-
randomised, retrospective design and non-overlapping treatment
periods for LDR–EBRT and HDR–EBRT. The non-overlapping time
periods could have introduced historical bias because of changes
in diagnostic imaging/staging, use of active surveillance protocols
and changes in treatment delivery. Different dose fractionation
schedules were used in the LDR–EBRT and HDR–EBRT cohorts. In
addition, post-implant PSA data was missing from some patients
leading to their exclusion from the analysis with more excluded
patients in the HDR–EBRT cohort (48 versus 12). There were also
some differences in baseline characteristics between the two
groups. The LDR–EBRT group had a slightly younger median age,
but they also had a greater proportion of high risk PCa. More
patients were evaluated in the HDR–EBRT group (171 versus
116), which could have introduced selection bias relating to treat-
ment eligibility criteria. A further limitation was that numbers of
patients at risk evaluable at each timepoint differed between the
two cohorts.
For patients treated in the initial period after introduction of
HDR–EBRT there may have been a learning curve which could
detrimentally influenced outcomes. The mean prostate V100 in
the HDR–EBRT increased from 96.6% (standard deviation 1.6%) in
2007 to 99.6% (standard deviation 0.7%) in 2012, demonstrating a
dosimetric improvement over this period. This can be explained
by technique experience, introduction of a PTV and improvements
in the dose optimisation class solution/algorithm. Hoskin et al.
reported that D90 and V100 were important dose predicators of
biochemical control of prostate cancer in their randomised control
trial cohort [36]. Current practice at our centre has evolved further
adopting in 2013 the GEC-ESTRO recommendations that VPTV100
should be at least 95% of the planning aim dose [4]. Future work
will further evaluate the impact of this learning curve and tech-
nique evolution.
In summary, we have observed a statistically significant differ-
ence in bPFS in favour of LDR–EBRT compared with HDR–EBRT.
Cumulative rates of grade 3 or above GU and GI toxicity were
greater for LDR–EBRT, although these differences were not statisti-
cally significant. Well conducted randomised trials directly com-
paring LDR–EBRT with HDR–EBRT are needed to determine
whether true differences in bPFS exist.5. Conclusions
This retrospective study suggests that LDR–EBRT may provide
more effective PSA control at 5 years compared with HDR–EBRT.
Direct comparison of these treatments through randomised trials
are recommended to investigate this hypothesis further.6. Sources of support
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